跳至主要内容
临床试验/NCT04616352
NCT04616352已完成不适用

Effect of Inappropriate Therapy With Cefuroxime in Adult Patients Hospitalized With Pyelonephritis

Universidad Nacional de Colombia1 个研究点 分布在 1 个国家目标入组 973 人开始时间: 2020年12月26日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
973
试验地点
1
主要终点
Readmission

研究概览

简要总结

Resistance to empirical antibiotic treatment has resulted in increased mortality and morbidity in serious infections caused by certain common resistant pathogens in the community. The risk for increased mortality has been also the motivation for recent guidelines that suggest early empirical antimicrobial treatment with broad spectrum antibiotics within a few hours of suspecting sepsis, regardless of the potential microorganism or infection focus. Resistance to second-generation cephalosporins among patients with community-acquired urinary tract infection by E. coli has exceeded 20% in an increasing number of institutions and communities, without being clear about the impact of such resistance on the effectiveness of treatment. This is especially important in urinary infections, since, in general, mortality is very low. We expect to establish if there is a relationship between inappropriate empirical therapy and morbidity (in terms of length of stay or readmission) among hospitalized patients with pyelonephritis treated with empirical cefuroxime therapy to help to define the need for a change in the current guidelines. These guidelines will have application not only in Colombia, but also in other countries in Latin America or other countries that still use this empirical therapy. It will also define the need for use of broader spectrum antibiotics in this clinical scenario.

详细描述

Objectives:

  1. Establish the relationship between inappropriate empirical cefuroxime therapy in adult patients hospitalized with pyelonephritis and hospital stay.
  2. Establish the relationship between inappropriate empirical cefuroxime therapy in adult patients hospitalized with pyelonephritis and readmission due to pyelonephritis.
  3. Establish the relationship between inappropriate empirical therapy with cefuroxime in adult patients hospitalized with pyelonephritis and the time to readmission caused pyelonephritis.

The investigators proposed a retrospective cohort of hospitalized pyelonephritis patients with empirical antimicrobial management with cefuroxime in one institution of third complexity level. Exposure is understood as resistance to cefuroxime, that is, the impact of inappropriate empirical cefuroxime therapy on patients receiving this antibiotic. Patients who are admitted to the cohort had the diagnosis of pyelonephritis and were hospitalized for intravenous antimicrobial treatment and are followed up to the following outcomes: hospital discharge, or readmission due to pyelonephritis to the same or another institution of the insurance network.

The study will be conducted following the Good Clinical Practices for Research and approval by the Research Ethics Committee (REC) or Investigation Research Boards (IRB) of the participating institutions. The clinical information will be collected through online forms based on the information in the electronic medical record. Microbiological information will be taken from clinical laboratory reports (Whonet ver 5.5., WHO). The accuracy of the information collected will be verified by evaluating 100% of the formats. A pilot test will be carried out after approval by the IRB (25 february, 2020). The information will be stored anonymously, discarding from the database personal information of the patient that might allow the identification. Variables collected from the Electronic Medical Record include demographic, clinical (comorbidities, clinical status) and microbiological information. Other variables include time to change antibiotic (if done) and time of use of antibiotic. Information for the outcomes proposed include length of stay (in days), readmission (new admission because of pyelonephritis in the following 30 days after the first episode), and time to readmission (in days).

A propensity score matching will be performed to diminish the risk of selection bias and unbalanced subjects. Alternatively, and inverse probability treatment weighting can be used to balance the variables included. Both models will be constructed using a logistic regression for the probability of cefuroxime resistant. Final comparison between the exposed population and control population will be done using survival curves for the time to hospital discharge.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Retrospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Age ≥ 18 years.
  • Clinical diagnosis of pyelonephritis.
  • Antibiotic treatment with cefuroxime.
  • Urine culture positive for Escherichia coli

排除标准

  • Use of antibiotic for less than 24 hours.
  • Not availability of antimicrobial susceptibility testing.
  • Use of urinary catheter for more than 30 days.

结局指标

主要结局

Readmission

时间窗: Up to 30 days after discharge

Proportion of patients admitted to hospital because of new episode of urinary tract infection

Time to hospital discharge

时间窗: Up to 30 days

Time since admission to hospital discharge

Time to readmission

时间窗: Up to 30 days after discharge

Time since discharge to readmission

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Jorge Alberto Cortes Luna

Primary investigator

Universidad Nacional de Colombia

研究点 (1)

Loading locations...

相似试验

招募中
不适用
Population Pharmacokinetics, Effectiveness and Safety of Cefuroxime in NeonatesInfectious Disease
NCT05388747Shandong University100
已完成
不适用
Antibiotic Usage and Resistance; Knowledge and Practices Before and After Educational SessionsAntibiotics
NCT04493008Misr International University310
进行中(未招募)
1 期
Cefuroxime and Piperacillin Concentrations in the Biliary SystemInfection in the biliary system such as cholecystitis and cholangitis both as acute infections and post-operative infections.MedDRA version: 20.0Level: LLTClassification code 10008618Term: Cholecystitis chronic NOSSystem Organ Class: 100000004871MedDRA version: 20.0Level: LLTClassification code 10008615Term: Cholecystitis acute NOSSystem Organ Class: 100000004871MedDRA version: 20.0Level: LLTClassification code 10008619Term: Cholecystitis NOSSystem Organ Class: 100000004871MedDRA version: 20.0Level: LLTClassification code 10004638Term: Bile duct stone with cholecystitisSystem Organ Class: 100000004871MedDRA version: 20.0Level: LLTClassification code 10007004Term: Calculus of gallbladder with acute cholecystitisSystem Organ Class: 100000004871MedDRA version: 20.0Level: LLTClassification code 10006995Term: Calculus of bile duct with acute cholecystitisSystem Organ Class: 100000004871MedDRA version: 20.0Level: LLTClassification code 10008606Term: Cholangitis acute NOSSystem Organ Class: 100000004871MedDRA version: 20.0Level: LLTClassification code 10008608Term: Cholangitis NOSSystem Organ Class: 100000004871MedDRA version: 20.0Level: LLTClassification code 10008607Term: Cholangitis chronic NOSSystem Organ Class: 100000004871MedDRA version: 20.1Level: LLTClassification code 10056952Term: Septic cholangitisSystem Organ Class: 100000004862MedDRA version: 23.0Level: LLTClassification code 10083504Term: Acute obstructive suppurative cholangitisSystem Organ Class: 100000004862
EUCTR2021-002629-95-DKDepartment of vascular surgery, Lillebaelt Hospital200
已完成
3 期
Ventilator-Associated Pneumonia/Hospital-Acquired Pneumonia Requiring Mechanical Ventilatory SupportPneumonia
NCT00050401Pfizer500
已完成
2 期
Cefuroxime vs Ceftriaxone for SSI Prevention in NeurosurgerySurgical Site InfectionAntibiotics Prophylaxis
NCT05398081Dr. Promise Tamunoipiriala Jaja96